CA2467521A1 - Anticorps se liant a blys selon un mode immunospecifique - Google Patents

Anticorps se liant a blys selon un mode immunospecifique Download PDF

Info

Publication number
CA2467521A1
CA2467521A1 CA002467521A CA2467521A CA2467521A1 CA 2467521 A1 CA2467521 A1 CA 2467521A1 CA 002467521 A CA002467521 A CA 002467521A CA 2467521 A CA2467521 A CA 2467521A CA 2467521 A1 CA2467521 A1 CA 2467521A1
Authority
CA
Canada
Prior art keywords
replaced
amino acid
blys
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002467521A
Other languages
English (en)
Inventor
Steven M. Ruben
Steven C. Barash
Gil H. Choi
Tristan J. Vaughan
David Hilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2467521A1 publication Critical patent/CA2467521A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

la présente invention concerne des anticorps et molécules connexes qui se lient à BLyS selon un mode immunospécifique. Elle concerne également des méthodes et des compositions permettant de détecter ou de diagnostiquer une pathologie ou des troubles en rapport avec une expression aberrante de BLyS, ou avec une fonction inappropriée de BLyS, Ces compositions renferment des anticorps ou des fragments ou des variants de BLyS, ou bien des molécules connexes qui se lient à BLyS selon un mode immunospécifique. Cette invention concerne en outre des méthodes ou des compositions permettant de prévenir, de traiter ou d'atténuer une pathologie ou des troubles en rapport avec une expression aberrante de BLyS, ou avec une fonction inappropriée de BLyS, par administration à un animal d'une dose efficace d'un ou plusieurs anticorps ou fragments d'anticorps, ou bien de molécules connexes se liant à BLyS selon un mode immunospécifique.
CA002467521A 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique Abandoned CA2467521A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US60/331,469 2001-11-16
US34081701P 2001-12-19 2001-12-19
US60/340,817 2001-12-19
PCT/US2002/036496 WO2003055979A2 (fr) 2001-11-16 2002-11-14 Anticorps se liant à blys selon un mode immunospécifique

Publications (1)

Publication Number Publication Date
CA2467521A1 true CA2467521A1 (fr) 2003-07-10

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002467521A Abandoned CA2467521A1 (fr) 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique

Country Status (4)

Country Link
EP (1) EP1456347A4 (fr)
AU (1) AU2002364954A1 (fr)
CA (1) CA2467521A1 (fr)
WO (1) WO2003055979A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
NZ517782A (en) 1999-08-17 2004-01-30 Biogen Inc A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
WO2002016411A2 (fr) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Polypeptides de fixation et procedes associes
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
AU2004251679C1 (en) 2003-06-05 2009-05-28 Genentech, Inc. Combination therapy for B cell disorders
WO2005012531A2 (fr) * 2003-08-01 2005-02-10 Genentech, Inc. Polypeptides de liaison avec sequences de diversite restreinte
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2267033A3 (fr) 2004-03-31 2011-03-30 Canon Kabushiki Kaisha Protéine de liaison or et utilisation en conséquence
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20080050381A1 (en) * 2004-08-31 2008-02-28 Tsutomu Takeuchi Antihuman Baff Antibody
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
DK2139517T3 (da) * 2007-03-27 2013-08-26 Zymogenetics Inc Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN107586339B (zh) * 2016-07-06 2023-01-20 尚华科创投资管理（江苏）有限公司 一种BLyS抗体及其制备方法和应用
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
KR20230047223A (ko) 2018-01-05 2023-04-06 노보 노르디스크 에이/에스 면역억제 없이 il-6 매개 염증을 치료하기 위한 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
CA2408617A1 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
ES2609016T3 (es) * 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci

Also Published As

Publication number Publication date
WO2003055979A3 (fr) 2003-12-18
EP1456347A2 (fr) 2004-09-15
AU2002364954A1 (en) 2003-07-15
WO2003055979A2 (fr) 2003-07-10
AU2002364954A8 (en) 2003-07-15
EP1456347A4 (fr) 2006-08-02

Similar Documents

Publication Publication Date Title
EP1294769B1 (fr) Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
US7220840B2 (en) Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) Antibodies that immunospecifically bind to B lymphocyte stimulator
CA2467521A1 (fr) Anticorps se liant a blys selon un mode immunospecifique
AU2001268427A1 (en) Antibodies that immunospecifically bind to blys
CA2363112A1 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
CA2419661A1 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
CA2476675A1 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
DK2281843T3 (en) Antibodies that immunospecifically bind to BLyS.
AU2007202950B2 (en) Antibodies that Immunospecifically Bind to Blys

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead